Precigen receives fast track designation for prgn-3006 ultracar-t® in patients with relapsed or refractory acute myeloid leukemia

–   acute myeloid leukemia (aml) is among the most common types of leukemia in adults – –   prgn-3006 ultracar-t previously  received orphan drug designation (odd) in patients with aml by the us food and drug administration (fda) – –   prgn-3006 ultracar-t has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity, and has demonstrated dose-dependent in vivo expansion and durable persistence – germantown, md. , april 4, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the fda has granted fast track designation for prgn-3006 ultracar-t® in patients with relapsed or refractory (r/r) aml (clinical trial identifier: nct03927261).
PGEN Ratings Summary
PGEN Quant Ranking